TriNetX Expands Global Genomic Data Network with Zetta Genomics Acquisition

TriNetX's Strategic Acquisition of Zetta Genomics

In a significant move to enhance its capabilities, TriNetX, the foremost federated health data network, announced on April 7, 2026, its acquisition of essential assets from Zetta Genomics, a leading healthcare technology firm based in Cambridge, UK. This strategic acquisition aims to bolster TriNetX's genomics data management and analytics capabilities, facilitating a more integrated approach to handling multiomic data. The integration of Zetta's flagship platform, XetaBase, is set to transform patient care delivery and clinical research by allowing healthcare providers to efficiently blend phenotypic and genomic data.

TriNetX has long been a key player in the health data landscape, empowering various organizations by offering access to extensive real-world patient data from over 11,000 healthcare provider sites across more than 20 countries. The company is known for connecting health systems, researchers, and businesses globally to help them make informed healthcare decisions. By acquiring Zetta Genomics, TriNetX is poised to enhance the quality of insights generated from vast datasets, ultimately benefiting both providers and patients alike.

Zetta's XetaBase is recognized as a robust multiomic capture and analytics platform, currently serving some of the most prominent healthcare providers, life sciences companies, and research institutions. The synergy between TriNetX and Zetta is not new; the two firms have worked collaboratively since 2024 on various genomics data programs, laying solid groundwork that facilitated this acquisition. Significant technical feasibility work has been completed during their partnership, enabling secure and efficient querying across genomic and phenotypic data.

As TriNetX Executive Chairman Jeff Margolis highlights, the acquisition of Zetta's XetaBase is not merely a transactional event; it is a pivotal milestone that underscores TriNetX's commitment to advancing multiomic-enabled research and supporting healthcare organizations in scaling their data infrastructures.

Dr. Jeffrey Brown, Chief Scientific Officer at TriNetX, echoed Margolis's sentiments, stating, "The aim of improving human health through data is significantly augmented by integrating XetaBase technology, which we believe is crucial for both clinical practice and scientific innovation."

The CEO of Zetta Genomics, Ignacio Medina Castello, expressed his pride in Zetta's achievements and anticipation for the future integration with TriNetX. He noted that their collaborative efforts have successfully demonstrated a secure and federated approach to connecting genomic and clinical data at scale. As Zetta joins the broader TriNetX ecosystem, their work aims to accelerate efforts in enhancing healthcare delivery and reach a wider audience of researchers and healthcare partners.

Conclusion

With this acquisition, TriNetX solidifies its position at the forefront of health data innovation. The integration of Zetta Genomics and its advanced XetaBase platform promises to revolutionize the management of genomic data and significantly improve the capabilities of healthcare providers. As the two companies unite their strengths, the future looks promising for advancements in patient care and clinical research across the globe.